ARTICLE | Clinical News
Latuda lurasidone regulatory update
November 1, 2010 7:00 AM UTC
FDA approved an NDA from Dainippon for Latuda lurasidone to treat schizophrenia. The company plans to launch the product next quarter. Latuda is a small molecule antagonist of dopamine D2 receptor, s...